PRODUCTS
Elite Cultivars cultivated under the Greek sun
By selecting elite cultivars and combining favorable natural growing conditions with pharmaceutical process control, Anthera Pharmaceuticals produces medical cannabis products designed for consistency, safety, and therapeutic reliability. Our cultivation and manufacturing systems are built to deliver reproducible quality, from genetics to finished product, in line with European regulatory standards.
DRIED FLOWER
Elite Cultivars
Our dried flower portfolio is built around carefully selected, well-characterized cultivars grown under controlled conditions. Each product is manufactured, tested, and released under EU-GMP, ensuring defined specifications, batch-to-batch consistency, and full traceability. These products are intended for medical use and supplied in pharmaceutical packaging designed to preserve quality and stability throughout shelf life.
Oral Solution
Future Products
CO2 Extraction | Terpene Fractionation
Anthera Pharmaceuticals is developing a portfolio of pharmaceutical oral solutions based on standardized cannabis extracts. Using controlled CO₂ extraction and terpene fractionation, we aim to produce formulations with defined, reproducible chemical profiles that reflect both cannabinoid content and key aromatic terpenes.
These future products are designed to meet the same EU-GMP manufacturing, quality control, and stability requirements as all Anthera medicines. Our development focus is on consistency, dosing accuracy, and long-term product reliability, in line with the expectations of patients, prescribers, and regulatory authorities.
CO₂ Extraction
- Sub- and super- critical CO2 extraction
- Terpene and cannabinoid fractionation
- Controlled, validated production
Refinement
- Gentle solvent processing
- Filtration and fraction enrichment
- Process parameter control
Distillation
- Short-path molecular distillation
- Purification and fraction refinement
- High-purity intermediates
